Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 3 of 3 entries
Sorted by: Best Match Show Resources per page
Ezetimibe: its novel effects on the prevention and the treatment of cholesterol gallstones and nonalcoholic Fatty liver disease.

Journal of lipids

de Bari O, Neuschwander-Tetri BA, Liu M, Portincasa P, Wang DQ.
PMID: 22132342
J Lipids. 2012;2012:302847. doi: 10.1155/2012/302847. Epub 2011 Nov 03.

The cholesterol absorption inhibitor ezetimibe can significantly reduce plasma cholesterol concentrations by inhibiting the Niemann-Pick C1-like 1 protein (NPC1L1), an intestinal sterol influx transporter that can actively facilitate the uptake of cholesterol for intestinal absorption. Unexpectedly, ezetimibe treatment also...

Cite
de Bari O, Neuschwander-Tetri BA, Liu M, et al. Ezetimibe: its novel effects on the prevention and the treatment of cholesterol gallstones and nonalcoholic Fatty liver disease. J Lipids. 2011;2012:302847doi: 10.1155/2012/302847.
de Bari, O., Neuschwander-Tetri, B. A., Liu, M., Portincasa, P., & Wang, D. Q. (2012). Ezetimibe: its novel effects on the prevention and the treatment of cholesterol gallstones and nonalcoholic Fatty liver disease. Journal of lipids, 2012302847. https://doi.org/10.1155/2012/302847
de Bari, Ornella, et al. "Ezetimibe: its novel effects on the prevention and the treatment of cholesterol gallstones and nonalcoholic Fatty liver disease." Journal of lipids vol. 2012 (2012): 302847. doi: https://doi.org/10.1155/2012/302847
de Bari O, Neuschwander-Tetri BA, Liu M, Portincasa P, Wang DQ. Ezetimibe: its novel effects on the prevention and the treatment of cholesterol gallstones and nonalcoholic Fatty liver disease. J Lipids. 2012;2012:302847. doi: 10.1155/2012/302847. Epub 2011 Nov 03. PMID: 22132342; PMCID: PMC3216277.
Copy Download .nbib Format: NLM
Therapy of gallstone disease: What it was, what it is, what it will be.

World journal of gastrointestinal pharmacology and therapeutics

Portincasa P, Ciaula AD, Bonfrate L, Wang DQ.
PMID: 22577615
World J Gastrointest Pharmacol Ther. 2012 Apr 06;3(2):7-20. doi: 10.4292/wjgpt.v3.i2.7.

Cholesterol gallstone disease is a common clinical condition influenced by genetic factors, increasing age, female gender, and metabolic factors. Although laparoscopic cholecystectomy is currently considered the gold standard in treating patients with symptomatic gallstones, new perspectives regarding medical therapy...

Cite
Portincasa P, Ciaula AD, Bonfrate L, et al. Therapy of gallstone disease: What it was, what it is, what it will be. World J Gastrointest Pharmacol Ther. 2012;3(2):7-20doi: 10.4292/wjgpt.v3.i2.7.
Portincasa, P., Ciaula, A. D., Bonfrate, L., & Wang, D. Q. (2012). Therapy of gallstone disease: What it was, what it is, what it will be. World journal of gastrointestinal pharmacology and therapeutics, 3(2), 7-20. https://doi.org/10.4292/wjgpt.v3.i2.7
Portincasa, Piero, et al. "Therapy of gallstone disease: What it was, what it is, what it will be." World journal of gastrointestinal pharmacology and therapeutics vol. 3,2 (2012): 7-20. doi: https://doi.org/10.4292/wjgpt.v3.i2.7
Portincasa P, Ciaula AD, Bonfrate L, Wang DQ. Therapy of gallstone disease: What it was, what it is, what it will be. World J Gastrointest Pharmacol Ther. 2012 Apr 06;3(2):7-20. doi: 10.4292/wjgpt.v3.i2.7. PMID: 22577615; PMCID: PMC3348960.
Copy Download .nbib Format: NLM
A pleiotropic role for the orphan nuclear receptor small heterodimer partner in lipid homeostasis and metabolic pathways.

Journal of lipids

Garruti G, Wang HH, Bonfrate L, de Bari O, Wang DQ, Portincasa P.
PMID: 22577560
J Lipids. 2012;2012:304292. doi: 10.1155/2012/304292. Epub 2012 Apr 22.

Nuclear receptors (NRs) comprise one of the most abundant classes of transcriptional regulators of metabolic diseases and have emerged as promising pharmaceutical targets. Small heterodimer partner (SHP; NR0B2) is a unique orphan NR lacking a DNA-binding domain but contains...

Cite
Garruti G, Wang HH, Bonfrate L, et al. A pleiotropic role for the orphan nuclear receptor small heterodimer partner in lipid homeostasis and metabolic pathways. J Lipids. 2012;2012:304292doi: 10.1155/2012/304292.
Garruti, G., Wang, H. H., Bonfrate, L., de Bari, O., Wang, D. Q., & Portincasa, P. (2012). A pleiotropic role for the orphan nuclear receptor small heterodimer partner in lipid homeostasis and metabolic pathways. Journal of lipids, 2012304292. https://doi.org/10.1155/2012/304292
Garruti, Gabriella, et al. "A pleiotropic role for the orphan nuclear receptor small heterodimer partner in lipid homeostasis and metabolic pathways." Journal of lipids vol. 2012 (2012): 304292. doi: https://doi.org/10.1155/2012/304292
Garruti G, Wang HH, Bonfrate L, de Bari O, Wang DQ, Portincasa P. A pleiotropic role for the orphan nuclear receptor small heterodimer partner in lipid homeostasis and metabolic pathways. J Lipids. 2012;2012:304292. doi: 10.1155/2012/304292. Epub 2012 Apr 22. PMID: 22577560; PMCID: PMC3346990.
Copy Download .nbib Format: NLM
Showing 1 to 3 of 3 entries